Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

NCT04827953 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Gemcitabine
DRUG: Nab paclitaxel
DRUG: NLM-001
DRUG: Zalifrelimab

Sponsor

Nelum Corp

Collaborators

[object Object]
[object Object]